• 1. West China School of Nursing, Sichuan University/Day Surgery Center, General Practice Medical Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
  • 2. Division of Gastrointestinal Surgery, Department of General Surgery, West China Hospital, Sichuan University/ West China School of Medicine in Sichuan University, Chengdu 610041, P. R. China;
  • 3. West China School of Nursing, Sichuan University/ West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
HUANG Mingjun, Email: hmj123123@126.com; JIANG Xiaolian, Email: jiang_xiaolian@126.com
Export PDF Favorites Scan Get Citation

Objective To analyze the impact of neoadjuvant regimens on prognosis in patients with rectal cancer in the current version of the Database from Colorectal Cancer (DACCA) database. Methods Patient information was extracted from the updated version of DACCA on November 24, 2022 according to the established screening criteria, and the following items were analyzed: gender, age, body mass index (BMI), marriage, economic conditions, degree of differentiation, neoadjuvant treatment regimen, and pTNM staging. According to the neoadjuvant treatment regimen, the patients were divided into three groups: chemotherapy group, chemotherapy combined radiotherapy group, and chemotherapy combined targeted therapy group, and the overall survival (OS) and disease-specific survival (DSS) of patients in the three groups were analyzed, and the influencing factors of OS and DSS were analyzed by univariate and multivariate Cox proportional hazard regression models. Results According to the screening criteria, 1 716 valid data were obtained from the DACCA database, of which 954 (55.6%) were in the chemotherapy group, 332 (19.3%) in the chemotherapy combined radiotherapy group, and 430 (25.1%) in the chemotherapy combined targeted therapy group. The differences in the Kaplan-Merier survival curves of patients with different neoadjuvant regimens for OS and DSS in the three groups were statistically significant (χ2=142.142, P<0.001; χ2=129.528, P<0.001). There were significant differences in OS rate and DSS rate between the three groups in 3 years and 5 years (P<0.001). Further comparison of different neoadjuvant therapy groups showed that the OS of the chemotherapy combined targeted therapy group was slightly better than that of the chemotherapy group in 3 years, however, OS and DSS in 5 years were slightly worse than those the chemotherapy group, but the difference were not statistically significant (P>0.05). The OS and DSS of the chemotherapy group and the chemotherapy combined targeted therapy group were better than those of the chemotherapy combined radiotherapy group in 3 years and 5 years, and the differences were statistically significant (P<0.01). The results of multivariate analysis showed that patients’ age, economic conditions, degree of tumor differentiation, new auxiliary scheme and pTNM staging were the influencing factors of OS and DSS. Conclusion Neoadjuvant treatment regimen will affect the long-term survival prognosis of rectal cancer patients.

Citation: MOU Min, LIU Hanlin, BAI Yuying, WANG Xiaodong, HUANG Mingjun, JIANG Xiaolian. Effect of neoadjuvant regimens on prognosis in patients with rectal cancer: a real-world study based on DACCA. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2024, 31(3): 301-308. doi: 10.7507/1007-9424.202401031 Copy

  • Previous Article

    CT and MR manifestations of hepatoid adenocarcinoma of the pancreas: a case report and literature review
  • Next Article

    Analysis of transcriptomic differences of duodenal neuroendocrine tumor accompanied by liver and lymph node metastases